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BACKGROUND & AIMS:
There are few data available on the real-life pharmacokinetic and pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin a4b7. We performed a prospective study of patients with inflammatory bowel diseases (IBDs) treated with vedolizumab to determine serum drug concentrations, formation of antivedolizumab antibodies (AVAs), and integrin a4b7 saturation.
METHODS:
We performed a prospective study of 106 patients with IBD (67 with Crohn's disease and 39 with ulcerative colitis) treated with vedolizumab from September 2014 through March 2017 at 2 tertiary medical centers in Israel. Clinical data and serum samples were collected before and during induction and maintenance therapy. Clinical remission was defined as Harvey-Bradshaw index scores below 5 or as Simple Clinical Colitis Activity Index scores of 3 or less. We measured serum levels of vedolizumab, AVAs, and markers of inflammation. Peripheral blood mononuclear cells were obtained from some patients at designated trough time points and CD3D CD45ROD T cells were isolated from 36 samples. Cells were incubated with fluorescentconjugated vedolizumab and flow cytometry was used to quantify a4b7 integrin saturation. We also performed flow cytometry analyses of CD3D CD45ROD lamina propria T cells isolated from intestinal mucosa of patients without IBD (non-IBD controls, n [ 6), patients with IBD not treated with vedolizumab (untreated IBD controls, n [ 8) , and patients with IBD treated with vedolizumab (n [ 15) .
RESULTS:
Clinical remission was achieved by 48 of 106 patients (45%) by week 6 and 50 of 106 patients (48%) by week 14 of treatment. The median level of vedolizumab at week 6 was higher in patients in clinical remission (40.2 mg/mL) than in patients with active disease (29.7 mg/mL; P [ .05). The median serum level of vedolizumab was significantly higher in patients with a normal level of Creactive protein (21.8 mg/mL vedolizumab) vs the level in those with a high level of C-reactive protein (11.9 mg/mL vedolizumab) during maintenance treatment (P [ .0006). The other clinical outcomes measured were not associated with median serum level of vedolizumab at any time point examined. AVAs were detected in 17% of patients during induction therapy and 3% of patients during maintenance therapy, but did not correlate with clinical outcomes. Flowcytometry analysis of peripheral blood memory T cells (n [ 36) showed near-complete occupancy of a4b7 integrin at weeks 2 and 14 and during the maintenance phase, regardless of response status or drug levels. Most intestinal CD3DCD45ROD memory T cells of healthy and IBD controls expressed a4b7 (72%; interquartile range, 56%-81%). In contrast, free a4b7 was detectable on only 5.6% of intestinal memory cells (interquartile range, 4.4%-11.2%) (P < .0001) from vedolizumab-treated patients, regardless of response.
T he leukocyte a4b7 integrin facilitates leukocyte homing to the gut via binding of Mucosal Addressin Cell Adhesion Molecule-1 on intestinal endothelium. [1] [2] [3] Vedolizumab is a monoclonal antibody against a4b7, which is efficacious for patients with moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). 4, 5 Although higher levels of anti-tumor necrosis factors, both infliximab and adalimumab, were associated with clinical remission and mucosal healing in UC and CD, [6] [7] [8] [9] data regarding the pharmacokinetics and pharmacodynamics of vedolizumab are still scarce.
The GEMINI trials have shown that vedolizumab drug levels were associated positively with clinical response at week 6. However, drug levels have not been reported for later time points, 10, 11 and it is still unknown whether therapeutic drug monitoring of vedolizumab could improve patient management. The regulatory submission of vedolizumab asserts its mechanism of action is mediated by blockade of a4b7 on target cells, predominantly memory T cells, thereby inhibiting these cells from binding to MADCAM1 and migrating into inflamed intestinal tissues. 12 In the GEMINI program, integrin-receptor saturation on target effector cells was shown with high (6 mg/kg) and low (2 mg/kg) dosing regimens of vedolizumab, but correlation of target occupancy with individual patient response status was not shown. 13 Moreover, there are hitherto no data on a4b7-receptor occupancy in the gut. The present study therefore aimed to assess, in a large prospective real-life cohort, the relationship between vedolizumab levels, clinicobiologic end points, and a4b7 target occupancy in the blood and the intestine.
Methods

Patient Population
This was a prospective observational study of inflammatory bowel disease (IBD) patients receiving scheduled vedolizumab therapy between September 2014 and March 2017 at 2 tertiary medical centers in Israel: Sheba Medical Center and Rambam Health Care Campus.
All patients who started scheduled vedolizumab therapy during the study period were enrolled after providing informed consent. Patients' clinical characteristics were recorded before drug initiation. Drug and anti-vedolizumab-antibody (AVA) serum levels, as well as inflammatory markers, were measured in pre-infusion sera collected prospectively throughout induction and maintenance therapy, and clinical scores were determined before each infusion. Baseline colonoscopy was performed at physician discretion and was not used universally before vedolizumab initiation. In a subset of patients, peripheral blood mononuclear cells (PBMCs), obtained at the designated trough time points, and lamina propria lymphocytes, obtained during lower endoscopy, also were collected. This study was approved by the medical centers' ethics committees and all patients provided written informed consent.
Clinical Scores
Clinical status was determined before each infusion prospectively by the Harvey-Bradshaw index (HBI) for CD and by the Simple Clinical Colitis Activity Index (SCCAI) for UC patients. 14, 15 Clinical remission was defined as HBI < 5 or as SCCAI 3. Clinical response was defined as a decrease of 3 points of the HBI and SCCAI scores. 16 Primary nonresponse was defined as cessation of vedolizumab therapy by week 14 owing to a lack of clinical response, as defined earlier. 17 Secondary loss of response was defined as clinical worsening necessitating drug discontinuation or additional intervention during the maintenance period. 18 
Assay Development for Vedolizumab Concentration Measurement
Integrin a4-b7 (2 mg/mL; R&D, Minneapolis, MN) was added to preplated anti-His-tag (4 mg/mL; R&D) wells of enzyme-linked immunosorbent assay (ELISA) plates (Nunc, Roskilde, Denmark). After drying, 100 mL of 1:1000 diluted serum was added and incubated for 60 minutes at room temperature. Plates then were washed and goat anti-human k chain horseradish-peroxidase-labeled antibody (Serotec, Oxford, UK) was added at a concentration of 66 ng/mL for 40 minutes. The results were read by an ELISA reader (EL-800; Biotek Instruments, Winooski, VT) and expressed as micrograms per milliliter. The level of detection of the assay was 3 ng/mL and the level of quantitation was 3 mg/mL. For assay validation, graded vedolizumab concentrations were added to vedolizumab-negative sera, showing significant correlation of signal optical density with the concentrations added (rho ¼ 1; P < .0001) (Supplementary Figure 1) .
Determination of Antivedolizumab Antibody Concentration
A drug-tolerant ELISA assay using an anti-human l-chain-conjugated detector antibody was developed. Briefly, 100 mL of 1:500 diluted serum was added to preplated 5 mg/mL vedolizumab (Takeda Pharma, Roskilde, Denmark) and incubated for 60 minutes. After washing, horseradish-peroxidase-labeled goat antihuman l-chain antibody (MP Biomedicals, Solon, OH) at a concentration of 33 ng/mL was added for 40 minutes and reacted with tetramethylbenzidine substrate. The results were read by ELISA reader EL-800 (Biotek Instruments) and expressed as microgram per milliliter equivalents after normalization vs graded concentrations of 9 to 1200 ng/mL of goat anti-human F(ab 0 )2 fragment antibody (MP Biomedicals). AVA levels greater than 30 mg/mL equivalent cut-off values were considered positive, as determined by 3 SDs greater than the mean of 30 unexposed controls.
Fluorescence-Activated Cell Sorting Analysis of a4b7 Occupancy on T Cells
Freshly obtained PBMCs and lamina propria (LP) lymphocytes were isolated and prepared as previously described. 19 Vedolizumab was biotinylated (EZ-LinkTM NHS-PEO solid Phase biotinylation kit; Thermo Scientific, Waltham, MA). Cells were co-stained with CD3 T-cell marker, CD45RO, as a marker of previously activated cells (surrogate for memory cells) and with 30 mcg/mL of biotinylated-vedolizumab-streptavidin-R-phycoerythrin or a biotinylated-IgG control antibody. The expression of a4b7 (vedolizumab-positive cells) on gated peripheral blood or lamina propria CD3þCD45ROþ memory T cells was determined by fluorescence-activated cell sorting analysis (Navios Flow Cytometer; Beckman Coulter) and results were analyzed by Kaluza software (Beckman Coulter). To examine the drug concentration that completely blocked all free membranal a4b7, graded concentrations of vedolizumab were added to PBMCs, cultured for 5 days in media alone, or after polyclonal stimulation with 5 mcg/mL muromonab-CD3 (Muromonab-CD3).
Statistical Analysis
Continuous variables were compared by the MannWhitney test, and the Fisher exact test was used for categoric data. The Wilcoxon test was used to compare paired samples. A receiver operating characteristic (ROC) analysis was performed for analysis of the discriminatory accuracy of vedolizumab levels for categoric variables. Correlations were analyzed by the Spearman rank test. One-way analysis of variance and the Cochran Q test were used to test the differences between quartiles.
Multivariable analysis was performed using backward logistic regression. All P values were 2-sided, and a P value less than .05 was considered statistically significant. All statistics were performed with MedCalc software (version 12.2.1.0; Mariakerke, East Flanders, Belgium).
Results
Demography and Clinical Outcomes
A total of 124 patients started vedolizumab treatment during the study period; 18 patients were excluded because of missing sera, nonconsent, pregnancy, or cessation of vedolizumab before the third infusion owing to reasons unrelated to clinical nonresponse. Thus, the study cohort consisted of 106 IBD (67 CD, 39 UC) patients. The median follow-up period for the study cohort 
Baseline Factor Association With Pharmacokinetics
Baseline albumin and C-reactive protein (CRP) values correlated significantly with weeks 2, 6, and 14 vedolizumab trough levels (Supplementary Table 1) , and albumin level quartiles were associated with increased week 14 vedolizumab trough levels (P < .001) (Figure 1 ). In addition, female sex, lower baseline weight, and younger age were associated with higher levels at week 2. Female sex was associated significantly with week 6 levels as well. On multivariate analysis, only baseline albumin level remained significantly correlated with both week 6 and 14 levels (Supplementary Table 1 ).
Association of Induction Period Drug Levels and Clinical and Biomarker Response
The median week 6 vedolizumab levels were higher in week 6 clinical remission vs nonremitter patients (40.2 mg/mL; IQR, 18.3-57.2 vs 29.7 mg/mL; IQR, 17.5-41.8, respectively; P ¼ .05) (Figure 2A ). On quartile analysis, a statistically significant difference in remission rate was noted between week 6 drug-level quartiles 2 and 3 and between 2 and 4 (P ¼ .02 and .006, respectively) ( Figure 2B ). However, drug levels were not associated with remission status at other time points (Supplementary Table 2 ). Week 6 drug levels in partially responding patients requiring interval shortening at week 10 (45.4 mg/mL; IQR, 19.6-84.2; n ¼ 12) were similar to levels in patients whose intervals were not shortened (33.9 mg/mL; IQR, 18.3-48; P ¼ .28). A subanalysis including only patients who did not receive steroids during induction (n ¼ 71) similarly showed a significant association of vedolizumab levels with clinical remission only for week 6 (median, 41.3 mg/mL; IQR, 19.8-40.5 vs 29.8 mg/mL; IQR, 24.6-53.4; P ¼ .04).
In an analysis of biomarker response, week 2 vedolizumab levels showed a significant, albeit weak, negative correlation with week 14 CRP values (rho ¼ -0.25; P ¼ .02) and week 6 drug levels were associated weakly with week 6 CRP values (rho ¼ -0.24; P ¼ .04) ( Figure 2C ). No association was detected between drug levels and CRP normalization for other time points (Supplementary Table 3) , and clinical remission was not predicted by any of the other clinical/demographic factors (Supplementary Table 5 ). A separate subgroup analysis for pharmacoinetic response correlation for CD (n ¼ 67) and UC patients (n ¼ 39) showed similar findings to those of the entire cohort (Supplementary Materials and Methods).
Maintenance Period Drug Level Association With Clinical Biomarker Response
Analysis of 140 serial sera obtained from 60 consecutive patients during vedolizumab maintenance therapy (week 22 onward) showed significantly higher median vedolizumab levels at time points with normal vs increased CRP (21.8 mg/mL; IQR, 12.9-40.5 vs 11.9 mg/mL; IQR, 5-26.5, respectively; P ¼ .0006) (Figure 3 ). In contrast, median levels in clinical responders did not differ from levels in nonresponders (15.9 mg/mL; IQR, 7.7-25 vs 14 mg/mL; IQR, 5.3-31.9, respectively; P ¼ .57). Drug levels in patients before interval shortening were similar to levels in patients not requiring this intervention, matched for the same time point (27.8 mg/mL; IQR, 11.4-45 vs 15.4 mg/mL; IQR, 7.1-26.2; P ¼ .09), and intra-individual temporal variations in vedolizumab levels appeared similar in responders vs those with loss of response (Supplementary Figure 3A and B) . Furthermore, week 6 levels among patients who went on to have sustained response during maintenance were not different than levels in patients with subsequent loss of response (35.7 mg/mL; IQR, 19-48.5 vs 31.5 mg/mL; IQR, 16.5-53, respectively; P ¼ .98).
Immunogenicity
AVAs were measured in 180 sera. Of these, 120 were consecutive (weeks, 2, 6, and 14) samples of 41 patients during induction (21 with week 14 clinical remission, 20 clinically active). An additional 60 sera samples obtained from 60 consecutive patients during maintenance therapy also were analyzed (30 of whom were clinically active at the time of sampling). Positive antibodies at weeks 2 or 6 were detected in 7 of 41 patients (17%): 3 of 21 (14.3%) responders and 4 of 20 (20%) of the nonresponders (P ¼ .63; odds ratio, 1.5; 95% CI, 0.3-7.7). AVAs were detected with zero drug levels in 1 patient and with measurable drug levels (ie, drug positive/AVA positive) in the other 6 patients, with the use of the described drug-tolerant assay. Only 2 of 60 (3%) patients during maintenance therapy were found to be AVA positive (1 AVA positive/drug positive in a patient in remission, 1 AVA positive/drug negative in a patient with loss of response).
Intestinal and Peripheral Blood a4b7 Integrin Target Occupancy in Relation to Drug Levels and Clinical Outcome
Peripheral blood lymphocytes were collected prospectively at weeks 0, 2, and 14 in 13 patients starting vedolizumab therapy (6 responders and 7 nonresponders to induction). The percentage of free (unbound) a4b7 on CD3þCD45ROþ memory T cells was determined by fluorescence-activated cell sorting analysis. The median free a4b7 (positive a4b7 CD45ROþ cells) at week 0 was 27% (IQR, 18%-31%), and sharply deceased to near-complete target occupancy at week 2 (0.09%; IQR, 0.03%-0.59%) and at week 14 (2%; IQR, 0.77%-3.4%; P < .0001 for both comparisons) ( Figure 4A and B) . Near-complete target occupancy at weeks 2 and 14 was universal and unrelated to response/nonresponse to induction or to drug levels at week 14 ( Figure 4B ). The percentage of positive a4b7 T cells before vedolizumab initiation (day 0) did not predict response to induction in the present cohort (n ¼ 13), or in an additional exploratory cohort (n ¼ 26, data not shown). Similar to the findings during induction, nearcomplete a4b7 occupancy also was found on T cells obtained during the maintenance phase (n ¼ 23), regardless of whether patients were in clinical response (n ¼ 12) or loss of response (n ¼ 11) ( Figure 4B ). Similar near-complete blockade of a4b7 also was found for naive T cells (CD3þCD45RO-, data not shown). Given these results, the minimal concentration of vedolizumab able to block PB T cell a4b7, in vitro, was explored (see Methods section). A near-complete blockade of a4b7 (<2% free a4b7) was apparent already with concentrations of 3 mg/mL of vedolizumab in unstimulated resting cells, whereas stimulated cells had higher baseline expression of a4b7 and required somewhat higher vedolizumab concentrations to achieve comparable target occupancy ( Figure 4C) .
Finally, mucosal samples were obtained during colonoscopies in healthy control individuals, IBD controls (not treated with vedolizumab), and IBD patients treated with vedolizumab (n ¼ 29), and LP T cells were isolated and stained as described earlier. CD3þCD45ROþ LP T cells in both healthy and IBD control individuals were predominantly a4b7 positive, regardless of the controls' disease activity state (median, 71%; IQR, 55.6%-81%; n ¼ 14). In contrast, in vedolizumab-treated patients, free a4b7 on intestinal memory cells was significantly lower (median CD3þCD45ROþa4b7þ, 5.6%; IQR, 4.4%-11.2%; n ¼ 15; P < .0001) (Figure 4D and E) . Intestinal a4b7 occupancy in vedolizumab-treated patients was similar in inflamed and noninflamed mucosa (5.6%; IQR, 4.4-11.2; n ¼ 15 vs 4.8%; IQR, 3.8-11.8; n ¼ 9; respectively; P ¼ .7) (Supplementary Table 6 ). There was also no difference in the rate of free a4b7þ on T cells among responders and nonresponders to therapy (data not shown).
Discussion
Vedolizumab is efficacious for moderate-to-severe CD and UC. 4, 5, 20, 21 Nevertheless, scarce data exist pertaining to its pharmacokinetics/pharmacodynamics, and data on its target occupancy in the gut are completely absent. This study showed a modest association of vedolizumab drug levels with some outcomes of clinical and biomarker response to therapy. It further showed a nearly full target a4b7-receptor occupancy on both peripheral blood and intestinal memory T cells, within a wide range of drug concentrations and regardless of response to therapy or not.
Similar to the GEMINI trials, 22 we also found body weight and albumin to correlate with induction drug concentration and identified female sex as an additional predictor, possibly owing to the lower average weight of females. However, the only predictor retained on multivariable analysis was albumin, whose correlation with drug levels was not only found for extreme albumin values, unlike the GEMINI analysis. This may be related to differences in neonatal Fc receptor salvage 23 and/or in fecal loss of albumin/IgG, which may be different for the present population compared with the GEMINI trial population. In the GEMINI 1 and 2 studies, vedolizumab drug level quartiles at week 6 were associated positively with week 6 clinical response. 10, 11 In the present cohort, week 6 levels were similarly higher in week 6 responders compared with nonresponders, regardless of concomitant steroid therapy. However, clinical outcomes at other time points were not predicted by week 2 or 6 levels. This was echoed in a recently published analysis of the GEMINI trial, in which no definite vedolizumab threshold level could be determined for discriminating remitters from nonremitters after consideration of covariates. 24 This could suggest that some detected drug-response associations may arise from multiple testing, implying further corroborating studies are imperative. Interestingly, a recent real-life study similarly did not find different vedolizumab levels between responders and nonresponders, although week 6 levels less than 19 mg/ mL were associated modestly with a subsequent need for interval shortening. 25 We could not reproduce such a correlation, possibly because of different cohort characteristics or size (106 patients in the present cohort vs 47 in the previously reported cohort), or because of variations in assay techniques or outcome definitions.
Vedolizumab levels were associated with biomarker response (CRP normalization), especially during maintenance treatment. Data on maintenance-phase drug levels and outcomes still are scant, but the present observations are in line with recent data from another real-world cohort, presented in abstract form. 26 Immunogenicity rates of vedolizumab were 17% during induction and 3% during maintenance, and were in agreement with the reported low incidence of AVA and with their limited clinical impact. 26, 27 As concluded by the Food and Drug Administration and European Medicines Agency, the mechanism of action of vedolizumab is blockade of a4b7, predominantly on memory T cells, to inhibit their MADCAM1-binding-mediated migration into intestinal tissue. 12 Earlier work showed that even a 2 mg/kg vedolizumab dose provided near-complete saturation of the integrin receptor, 28 thereby suggesting the need to elucidate the pharmacodynamic impact of fluctuations of vedolizumab exposure within the current dosing scheme. Recently, higher baseline messenger RNA expression of integrin aEb7, and its decrease after therapy, were correlated with response to etrolizumab, an anti-b7 integrin antibody. 29 However, the rate of a4b7 occupancy with this agent was not reported. The present findings show target membranal a4b7 integrin on peripheral blood memory T cells to be nearly fully occupied during both induction and maintenance with vedolizumab and regardless of clinical response status. Whether these results indicate blocking of a4b7 by vedolizumab or postbinding internalization of the a4b7-vedolizumab complex still is unclear, but even the latter implies a near-complete binding of a4b7 by vedolizumab before putative internalization.
Similar to findings in blood, near-full receptor saturation was shown, also on activated T cells in the intestinal mucosa, indicating in situ blockade of T cells by vedolizumab and/or the effective prevention of these cells from migration to the gut. Full receptor occupancy was evident throughout a wide range of drug concentrations and was unrelated to response status, thereby arguing against subdosed vedolizumab (being unable to block its target in full) as the cause for suboptimal response in nonresponders. Conversely, however, these data may hint toward other mechanisms underlying the biologic effect of vedolizumab or its lack thereof, such as receptor occupancy on other T-cell subsets, 30 which hypothetically may require higher drug concentration for optimized effect.
There were several limitations to our study. Vedolizumab levels were measured using an in-house novel validated ELISA-based assay; thus, corroborating studies using other assays are pertinent. Nonetheless, the vedolizumab concentrations herein are in agreement with those reported in the GEMINI trials, and a high accuracy for detecting exogenous vedolizumab was shown ( Supplementary Figure 1) , thus supporting the validity of the observations. Second, various clinical biomarker end points in relation to drug levels were assessed, but endoscopic outcomes were not evaluated.
In conclusion, in this real-life prospective pharmacokinetic cohort of vedolizumab-treated IBD patients, drug levels were associated with some, albeit not all, clinical outcomes of induction and with CRP normalization during maintenance. Peripheral blood and intestinal target a4b7 integrin is nearly fully occupied by vedolizumab throughout a wide range of drug concentrations and regardless of therapy. These pharmacokinetic-pharmacodynamic data suggest that within current dosing schemes, drug levels in most nonresponders still are sufficient to block the a4b7 target molecule, indicating the need to explore additional modes of action of vedolizumab and to elucidate other mechanisms underlying nonresponse to the drug.
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Supplementary Materials and Methods
Induction Period Drug Levels and Clinical and Biomarker Response Subanalyses Among Crohn's Disease and Ulcerative Colitis Patients
Among CD patients (n ¼ 67), similar to the general study population, week 6 vedolizumab levels were associated with clinical remission at week 6 (median levels, 47.7 mg/mL; IQR, 18.4-61 vs 33 mg/mL; IQR, 21.2-42.5; P ¼ .037 in patients in remission vs clinically active patients, respectively). However, ROC analysis showed only modest discriminatory accuracy (area under the receiver operating characteristic curve, 0.66; 73% sensitivity, 70.3% specificity for drug level > 37.8 mg/mL; P ¼ .055; odds ratio, 5.5 for remission with levels >37.8 mg/mL; P < .01) (Supplementary Figure 2A) . All other associations were insignificant among CD patients (Supplementary Table 7) . A separate analysis of weeks 2 and 6 levels in relation to HBI values yielded no significant association either (data not shown).
Among UC patients (n ¼ 39), week 2 median vedolizumab levels were significantly higher (55.8 mg/ mL; IQR, 35.4-80.8 mg/mL) in patients who went on to have clinical remission at week 6, compared with 29.9 mg/mL (IQR, 24-47.7) in patients without clinical remission at week 6 (P ¼ .02). ROC analysis showed that vedolizumab week 2 levels greater than 32.7 mg/ mL had a 90% sensitivity and a 61.1% specificity for clinical remission at week 6 among UC patients (area under the receiver operating characteristic curve, 0.73; P ¼ .01; odds ratio, 8 for remission with a drug level > 32.7 mcg/mL; P ¼ .019) (Supplementary Figure 2B) . Nevertheless, subanalyses of vedolizumab levels among UC patients at week 6 regarding clinical remission and clinical score (SCCAI) at weeks 6 or 14 did not yield statistically significant correlations (Supplementary Table 8 ).
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Supplementary Figure 1 . Correlation between graded concentrations of exogenously added vedolizumab to unexposed serum and ELISA reading by optical density. 
